Steris
About: Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Additionally, Steris sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.
Employees: 18,179
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
502% more call options, than puts
Call options by funds: $18.1M | Put options by funds: $3.01M
27% more first-time investments, than exits
New positions opened: 76 | Existing positions closed: 60
3% more capital invested
Capital invested by funds: $22B [Q2] → $22.5B (+$553M) [Q3]
1% more funds holding
Funds holding: 740 [Q2] → 746 (+6) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 8 [Q2] → 8 (+0) [Q3]
6.22% less ownership
Funds ownership: 101.58% [Q2] → 95.35% (-6.22%) [Q3]
19% less repeat investments, than reductions
Existing positions increased: 245 | Existing positions reduced: 301
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
JMP Securities David Turkaly 36% 1-year accuracy 9 / 25 met price target | 26%upside $265 | Market Outperform Reiterated | 18 Nov 2024 |
Stephens & Co. Jacob Johnson 58% 1-year accuracy 11 / 19 met price target | 24%upside $260 | Overweight Reiterated | 7 Nov 2024 |
Piper Sandler Jason Bednar 37% 1-year accuracy 13 / 35 met price target | 24%upside $260 | Overweight Upgraded | 24 Oct 2024 |
Financial journalist opinion
